Phase II Trial of Veliparib in Patients with Previously-Treated BRCA-Mutated Pancreas Ductal Adenocarcinoma

PURPOSE: BRCA-associated cancers have increased sensitivity to PARP inhibitors (PARPi). This single arm, non-randomized, multicenter phase II trial evaluated the response rate of velparib in patients with previously-treated BRCA1/2 or PALB2 mutant pancreatic adenocarcinoma (PDAC). METHODS: Patients...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Eur J Cancer
Main Authors: Lowery, Maeve A., Kelsen, David P., Capanu, Marinela, Smith, Sloane C., Lee, Jonathan W., Stadler, Zsofia K, Moore, Malcolm J, Kindler, Hedy L., Golan, Talia, Segal, Amiel, Maynard, Hannah, Hollywood, Ellen, Moynahan, MaryEllen, Salo-Mullen, Erin E., Kinh Gian Do, Richard, Chen, Alice P., Yu, Kenneth H., Tang, Laura H., O’Reilly, Eileen M.
Format: Artigo
Jezik:Inglês
Izdano: 2017
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7351022/
https://ncbi.nlm.nih.gov/pubmed/29223478
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejca.2017.11.004
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki